ProCE Banner Activity

ELEVATE TN: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naive CLL

Slideset Download
Conference Coverage
Acalabrutinib with or without obinutuzumab significantly improved PFS compared with obinutuzumab plus chlorambucil.

Released: December 11, 2019

Expiration: December 09, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company